CA-4948 |
| Katalog-Nr.GC32748 |
CA-4948 ist ein selektiver, potenter und oral aktiver Inhibitor der Interleukin-1-Rezeptor-assoziierten Kinase 4 (IRAK4), extrahiert aus dem Patent WO2015104688 (Beispiel 1).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1801343-74-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CA-4948 is a selective and potent IRAK4 inhibitor.
CA-4948 is a selective and potent IRAK4 inhibitor which can be used as a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling. CA-4948 exhibits favorable DMPK properties, oral bioavailability, and is well tolerated in mice. Furthermore, CA-4948 is previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models[1].
[1]. Robert N. Booher, et al. Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma. AACR Annual Meeting 2017; April 1-5, 2017;
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *